Crossmark

Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins

Crossref DOI link: https://doi.org/10.1016/j.jim.2018.03.009

Published Print: 2018-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wu, Chung-An M.

Roth, Theodore L.

Baglaenko, Yuriy

Ferri, Dario M.

Brauer, Patrick https://orcid.org/0000-0001-7788-5204
Zuniga-Pflucker, Juan Carlos https://orcid.org/0000-0003-2538-3178
Rosbe, Kristina W.

Wither, Joan E.

Marson, Alexander

Allen, Christopher D.C.
Funding

Funding for this research was provided by:

University of California, San Francisco

National Institute of Allergy and Infectious Diseases

National Institutes of Health (R01AI130470)

Canadian Institutes of Health Research (PJT-148948)

Howard Hughes Medical Institute

Pew Charitable Trusts

Burroughs Wellcome Fund
License Information

Text and Data Mining valid from 2018-06-01

Text and Data Mining valid from 2018-06-01

Accepted Manuscript valid from 2019-04-25
More Information

This article is maintained by: Elsevier

Article Title: Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins

Journal Title: Journal of Immunological Methods

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jim.2018.03.009

Content Type: article

Copyright: © 2018 Elsevier B.V. All rights reserved.